Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q3 EPS of ($0.30), $0.05 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $118.7 million versus the consensus estimate of $114.22 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.